Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion type Assertion NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_head.
- NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion description "[A phase I clinical trial was conducted to evaluate the safety and activity of the neoadjuvant intraprostatic injection of GLIPR1 expressing adenovirus for intermediate or high-risk localized prostate cancer before radical prostatectomy (RP).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_provenance.
- NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion evidence source_evidence_literature NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_provenance.
- NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion SIO_000772 21933889 NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_provenance.
- NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion wasDerivedFrom befree-2016 NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_provenance.
- NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_assertion wasGeneratedBy ECO_0000203 NP925153.RA7P73MgnNdSKDexDJ_fBy_NntyKh_Tn6gDmLqf2UfURg130_provenance.